Has Mark Onaitis, MD received payments from drug or device companies?

Yes. Drug and device makers reported $207,207 in general payments to Mark Onaitis, MD across 225 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mark Onaitis, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mark Onaitis, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mark Onaitis, MD

Thoracic Surgery (Cardiothoracic Vascular Surgery) · San Diego, CANPI 1841310638

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $141,915 of the $207,207 with a category attached, or 68.5%. 13 manufacturers reported payments, led by Intuitive Surgical at 58.5% of the total. Reporting peaked in 2022 at $55,132 and has fallen 83.4% since, to $9,171 in 2025. Among thoracic surgery (cardiothoracic vascular surgery) clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$207,207in general payments, 2019–2025

Across 225 payments — averaging $920.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Intuitive Surgical$121K
Medtronic$45K
Covidien LP$30K
Serpex Medical Inc$9K
AstraZeneca$1K
Galvanize Therapeutics, Inc$330
plus $752 from 7 others

$18,429in research payments, 2019–2025

Across 5 payments — averaging $3685.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Medtronic$18K
Transmedics, Inc.$804

What the payments were for

Consulting fees$141,91568%
Speaking & faculty fees$40,55020%
Travel & lodging$12,6676%
Food & beverage$7,5754%
Education$4,5002%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Intuitive Surgical	65	$121,315
Medtronic	101	$44,944
Covidien LP	36	$29,718
Serpex Medical Inc	4	$8,798
AstraZeneca	4	$1,350
Galvanize Therapeutics, Inc	3	$330
Davol Inc.	5	$262
Atricure, Inc.	1	$189
Boston Scientific	1	$122
E.r. Squibb & Sons, L.L.C.	1	$60
Johnson & Johnson	1	$47
Edwards Lifesciences	2	$42
On Target Laboratories, Inc	1	$31

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Da Vinci Surgical System$120,351
LigaSure$14,190
Sonicision$5,500
Signia$3,336
IMFINZI$1,163
ALIYA SYSTEM$315
ATRICURE CRYOICE CRYOSPHERE CRYOABLATION SYSTEM$189
Endo GIA$163
EXALT$122
PROGEL$122
ENDO GIA ULTRA$101

How this compares

$207,207 in reported general payments places this provider in the 95th percentile of 546 thoracic surgery (cardiothoracic vascular surgery) providers in California.

See all thoracic surgery (cardiothoracic vascular surgery) providers in California →

Medicare billing

Part B allowed, 2024

$99,006

Medicare patients

116

Services billed

234

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Gabapentin	21	$291

Paid to pharmacies, not to this prescriber.

Other thoracic surgery (cardiothoracic vascular surgery) in San Diego

James HempSan Diego$244K
Gert PretoriusSan Diego$110K
Robert AdamsonSan Diego$82K
Thomas FogartyPortola Valley$3.7M
Steven GundryPalm Springs$1.6M
Armin KiankhooySaint Helena$941K
Ara KlijianMurrieta$916K
Gregory FontanaThousand Oaks$875K
Gansevoort DunningtonSaint Helena$764K
Wilson TsaiWalnut Creek$680K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →